Amgen (AMGN)

Executive Summary

Amgen is a global biotechnology leader with a $188.99B market cap, renowned for its innovative biologic medicines across cardiovascular, oncology, and rare disease areas. The company's robust commercial portfolio includes blockbusters like Prolia, Repatha, and Enbrel, while its pipeline targets high-potential opportunities in obesity, inflammation, and oncology. Recent acquisitions, including Horizon Therapeutics, have added Tepezza and Krystexxa, further diversifying revenue. Amgen's strong R&D focus, combined with its biosimilar franchise, positions it for sustained growth amidst patent expirations. Near-term catalysts from key Phase 3 readouts could significantly impact valuation, though competition in obesity and pricing pressures remain risks.

Upcoming Catalysts (preview)

• Q4 2026AMG 133 (maridebart cafraglutide) Phase 3 obesity data70% success
• H1 2026Rosnilimab Phase 3 rheumatoid arthritis topline results65% success
• Q3 2026Sotorasib label expansion in colorectal cancer (CodeBreaK 300 readout)50% success